Abstract: Disclosed is an automatic hoisting and transporting method for a tower crane, the method including: building a three-dimensional grid model for a construction site, and generating a grid node set; generating an obstacle node set and a feasible area node set; obtaining coordinates of an initial node and an end node; planning a hoisting and transporting path from the initial node to the end node, and generating corresponding operating parameters; controlling the tower crane to transport an object according to the operating parameters, and calculating a swing range of the hoisted and transported object and a swing arm at a current position; determining whether a collision may occur; and predicting whether the tower crane may be overturned. The method realizes automatic hoisting and transporting of the tower crane. The object does not collide with an obstacle during hoisting and transporting, thereby ensuring safe operation of the tower crane.

Abstract: The invention provides 2-(substituted phenylhetero) aromatic formate FTO inhibitors, a preparation method thereof, and applications thereof. Specifically, disclosed in the present invention are a 2-(substituted phenylhetero) aromatic formate compound represented by the following formula (I), and a pharmaceutically acceptable salt, a hydrate or a solvate thereof, which can be used as an FTO targeting inhibitor for treating diseases associated with FTO targets, including obesity, metabolic syndrome (MS), type 2 diabetes (T2D), Alzheimer's diseases, and cancers such as breast cancers, small-cell lung cancers, human bone marrow rhabdomyosarcoma, pancreatic cancer, malignant glioblastoma and the like.

Abstract: The invention provides 2-(substituted phenylhetero) aromatic formate FTO inhibitors, a preparation method thereof, and applications thereof. Specifically, disclosed in the present invention are a 2-(substituted phenylhetero) aromatic formate compound represented by the following formula (I), and a pharmaceutically acceptable salt, a hydrate or a solvate thereof, which can be used as an FTO targeting inhibitor for treating diseases associated with FTO targets, including obesity, metabolic syndrome (MS), type 2 diabetes (T2D), Alzheimer's diseases, and cancers such as breast cancers, small-cell lung cancers, human bone marrow rhabdomyosarcoma, pancreatic cancer, malignant glioblastoma and the like.